Sun Pharmaceutical Industries has been granted a patent for deuterated D-serine and its derivatives, including methods for treating various neurological and psychiatric conditions such as epilepsy, Parkinson’s disease, Alzheimer’s disease, and major depressive disorder, by administering an effective amount of the compound. GlobalData’s report on Sun Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sun Pharmaceutical Industries, Nanoparticle drug conjugates was a key innovation area identified from patents. Sun Pharmaceutical Industries's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Deuterated d-serine for treating neurological disorders
The granted patent US12029712B2 outlines a method for treating a variety of neurological and psychiatric conditions, including epilepsy, NMDAR encephalitis, Parkinson's disease, Alzheimer's disease, and several forms of depression and cognitive deficits. Central to this method is the administration of an effective amount of a compound referred to as Compound 100. The claims specify that this compound can be administered orally, in unit doses ranging from 1 to 10 grams per day, with particular emphasis on achieving high levels of deuterium incorporation and stereomeric purity. The patent also details specific parameters for the compound, such as maintaining less than 2% of its enantiomer and allowing for natural isotopic abundance of non-deuterium atoms.
Further claims refine the treatment method, particularly for NMDAR encephalitis, emphasizing the need for at least 90% deuterium incorporation and at least 90% stereomeric purity. The patent includes variations in dosage, suggesting amounts from 1 to 5 grams per day, and specifies that the compound can be delivered in various unit dose forms. The claims also highlight the potential for Compound 100 to enhance NMDA receptor function, which may be relevant for the treatment of the specified conditions. Overall, the patent presents a comprehensive approach to utilizing Compound 100 for addressing significant cognitive and mood disorders, with a focus on precise formulation and administration parameters.
To know more about GlobalData’s detailed insights on Sun Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
